Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 14, 2010

NeoPharm : Orphan Drug Application Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis

neopharmMar 10, 2010 - NeoPharm, Inc. (Other OTC: NEOL.PK), announced that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. IPF is the most deadly disease of the lungs in humans with very high morbidity. It is estimated that at least 55,000 patients are diagnosed with IPF each year in America and about 45,000 patients die each year with the disease. There is currently no proven effective treatment for the cure of this lethal disease...NeoPharm's Press Release -